In vivo testing of drug-linker stability

Methods in Molecular Biology

Volumn 1045, Issue , 2013, Pages 101-116

  Abecassis, Pierre Yves ^a   Amara, Céline ^a  

^a SANOFI   (France)

Author keywords

Antibody drug conjugate (ADC); Biotherapeutics; Cytotoxic; Drug to antibody ratio (DAR); Enzyme linked immunosorbent assays (ELISA); High resolution mass spectrometry (HRMS); Linker; Monoclonal antibody (mAb); Pharmacokinetic (PK); Total antibody; Turbulent flow chromatography coupled to mass spectrometry (TFC MS MS)

Indexed keywords

ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHROMATOGRAPHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; FEMALE; IMMUNOASSAY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCEDURES; TANDEM MASS SPECTROMETRY; TURBULENT FLOW CHROMATOGRAPHY;

EID: 84934438619     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-541-5_6     Document Type: Article

References (30)

1. Wu AM, Senter PD (2005) Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137-1146
2. Lambert JM (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 5:543-549
3. Kratz F, Muller IA, Ryppa C, Warnecke A (2008) Prodrug strategies in anticancer chemotherapy. ChemMedChem 3:20-53
4. Mould DR, Sweeney KR (2007) The pharmacokinetics and pharmacodynamics of monoclonal antibodies -mechanistic modeling applied to drug development. Curr Opin Drug Discov Dev 10(1):84-96
5. Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14:154-169
6. Stephan JP, Kozak KR, Wong WL (2011) Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. Bioanalysis 3(6):677-700
7. Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA, Bernstein I (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 13:40-46
8. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellström I, Hellström KE (1993) Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261:212-215
9. Chari RVJ (2008) Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res 41:98-107
10. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290
11. Meister A, Anderson ME (1983) Glutathione. Annu Rev Biochem 52:711-760
12. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM (2011) SAR3419: An anti-CD19-Maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 17(20):6448-6458
13. Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, Perrone G, Tai YT, Cirstea D, Raje NS, Uherek C, Dalken B, Aigner S, Osterroth F, Munshi N, Richardson P, Anderson KC (2009) The monoclonal antibody nBT062conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 15:4028-4037
14. Erickson HK, Lambert JM (2012) ADME of antibody-maytansinoid conjugates. AAPS J 14 (4):799-805
15. Koblinski JE, Ahram M, Sloane BF (2000) Unravelling the role of proteases in cancer. Clin Chim Acta 291:113-135
16. U.S. Food and Drug Administration (2011) FDA approves adcetris to treat two types of lymphoma, for immediate release: 19 Aug 2011. U.S. Food and Drug Administration, Silver Spring, MD, 20993
17. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778-784
18. Erickson HK, Park PU,Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blattler WA (2006) Antibodymaytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66:4426-4433
19. Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX (2010) Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 16(19):4769-4778
20. Junutula JR, Bhakta S, Raab H, Ervin KE, Eigenbrot C, Vandlen R, Scheller RH, Lowman HB (2008) Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods 332:41-52
21. Wang L, Amphlett G, Blattler WA, Lambert JM, Zhang W (2005) Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 14:2436-2446
22. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD,Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26 (8):925-932
23. Lin K, Tibbitts J (2012) Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 29(9):2354-2366
24. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, McDonald PJ, Hass PE, Eigenbrot C, Nguyen T, Solis WA, Fuji RN, Flagella KM, Patel D, Spencer SD, Khawli LA, Ebens A, Wong WL, Vandlen R, Kaur S, Sliwkowski MX, Scheller RH, Polakis P, Junutula JR (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody drug conjugates. Nat Biotechnol 30:184-189
25. Baker MA, Roncari DAK, Taub RN, Mohanakumar T, Falk JA, Grant S (1982) Characterization of compounds shed from the surface of human leukemic myeloblasts in vitro. Blood 60:412-419
26. Black PH (1980) Shedding from the cell surface of normal and cancer cells. Adv Cancer Res 32:75-199
27. Lu Y, Wong WL, Meng YG (2006) A high throughput electrochemiluminescent cellbinding assay for therapeutic anti-CD20 antibody selection. J Immunol Methods 314:74-79
28. Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, Senter PD, Wahl AF (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 11:843-852
29. Stephan JP, Chan P, Lee C, Nelson C, Elliott JM, Bechtel C, Raab H, Xie D, Akutagawa J, Baudys J, Saad O, Prabhu S, Wong WL, Vandlen R, Jacobson F, Ebens A (2008) Anti-CD22-MCC-DM1 and MC-MMAF conjugates: Impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem 19(8):1673-1683
30. Fischer SK, Yang J, Anand B, Cowan K, Hendricks R, Li J, Nakamura G, Song A (2012) The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: Case studies. MAbs 4(5):623-631